In a phase 3 clinical trial, chronic night driving impairment in patients who underwent keratorefractive procedures improved after treatment with phentolamine ophthalmic solution 0.75%, according to a press release from Opus Genetics.
In the pivotal, double-masked LYNX-2 trial, 199 patients who reported decreased visual acuity under mesopic low contrast conditions following keratorefractive surgery were randomly assigned to receive either phentolamine or placebo and observed for 6 weeks. After 15 days of nightly administration in both eyes, 17.3% of treated patients had an improvement of 15 or